Regeneron (REGN) Misses Q1 EPS by 15c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Regeneron Pharma (REGN) PT Raised to $400 at Barclays Following 1Q Report; 'Initial Strength of the Dupixent Launch'
May 5, 2017 2:46 PM EDTBarclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $400.00 (from $375.00) while maintaining a Equalweight rating, following the company's first quarter earnings report.
Analyst Geoff Meachem notes the company produced revenues above consensus, but missed on earnings per share print, as investors focus on the strong Dupixent launch.
... MoreRegeneron Pharma (REGN) PT Raised to $475 at Cowen
May 4, 2017 3:39 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $475.00 (from $380.00) while maintaining a Market Perform rating following Q1 results.
Analyst Phil Nadeau is updating estimates to reflect Dupixent's fast start, Eylea's deceleration.
FY 2017 EPS goes from $12.25 to $1.25 and FY 2018 EPS goes from $14.90 to $13.20.
... More